Randomized Controlled Pilot Study of 2 Weeks' Treatment With High Cutoff Membrane for Hemodialysis Patients With Elevated C-Reactive Protein

Artificial Organs

Volumn 36, Issue 10, 2012, Pages 886-893

  Fiedler, Roman ^a   Neugebauer, Felix ^a   Ulrich, Christof ^a   Wienke, Andreas ^a   Gromann, Cora ^a   Storr, Markus ^b   Böhler, Torsten ^b   Seibert, Eric ^a   Girndt, Matthias ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b Gambro Research   (Germany)

Author keywords

C reactive protein; High cutoff membrane; High flux dialysis; Inflammation

Indexed keywords

ARTIFICIAL ORGANS; BODY FLUIDS; CHEMICAL ACTIVATION; HEMODIALYZERS; PATHOLOGY; PATIENT TREATMENT; PROTEINS;

ADVERSE EVENTS; C-REACTIVE PROTEINS; CHRONIC INFLAMMATION; HEMODIALYSIS PATIENT; HIGH CUTOFF MEMBRANE; HIGH FLUX; HIGH-FLUX DIALYSIS; MONOCYTE ACTIVATION; PILOT STUDIES; PROINFLAMMATORY CYTOKINES;

DIALYSIS;

C REACTIVE PROTEIN; CD14 ANTIGEN; CD16 ANTIGEN; CHOLINESTERASE;

AGED; ARTICLE; ARTIFICIAL KIDNEY; CELL ACTIVATION; CELL SUBPOPULATION; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIALYSIS MEMBRANE; DIZZINESS; DOUBLE BLIND PROCEDURE; DYSURIA; ENZYME ACTIVITY; FEMALE; FEVER; HEMODIALYSIS PATIENT; HIGH CUTOFF MEMBRANE; HIGH FLUX MEMBRANE; HUMAN; HYPOTENSION; LUNG DISEASE; MALE; MONOCYTE; MUSCULOSKELETAL PAIN; PILOT STUDY; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEPLETION; RANDOMIZED CONTROLLED TRIAL; RASH; SAFETY; SHUNT THROMBOSIS;

EID: 84867189628     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/j.1525-1594.2012.01479.x     Document Type: Article

References (29)

1. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999;55:648-58.
2. Bologa RM, Levine DM, Parker TS, etal. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998;32:107-14.
3. Kawaguchi T, Tong L, Robinson BM, etal. C-reactive protein and mortality in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephron Clin Pract 2011;117:c167-78.
4. Stenvinkel P, Ketteler M, Johnson RJ, etal. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia-the good, the bad, and the ugly. Kidney Int 2005;67:1216-33.
5. Heine GH, Ulrich C, Seibert E, etal. CD14(++)CD16(+) monocytes but not total monocyte numbers predict cardiovascular events in dialysis patients. Kidney Int 2008;73:622-9.
6. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-26.
7. Gottsäter A, Forsblad J, Matzsch T, etal. Interleukin-1 receptor antagonist is detectable in human carotid artery plaques and is related to triglyceride levels and Chlamydia pneumoniae IgA antibodies. J Intern Med 2002;251:61-8.
8. Schieffer B, Schieffer E, Hilfiker-Kleiner D, etal. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 2000;101:1372-8.
9. Ulrich C, Heine GH, Seibert E, Fliser D, Girndt M. Circulating monocyte subpopulations with high expression of angiotensin-converting enzyme predict mortality in patients with end-stage renal disease. Nephrol Dial Transplant 2010;25:2265-72.
10. Ulrich C, Seibert E, Heine GH, Fliser D, Girndt M. Monocyte angiotensin converting enzyme expression may be associated with atherosclerosis rather than arteriosclerosis in hemodialysis patients. Clin J Am Soc Nephrol 2011;6:505-11.
11. Kudo S, Goto H. Intrarenal handling of recombinant human interleukin-1alpha in rats: mechanism for proximal tubular protein reabsorption. J Interferon Cytokine Res 1999;19:1161-8.
12. Rostaing L, Chatelut E, Payen JL, etal. Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. J Am Soc Nephrol 1998;9:2344-8.
13. Vanholder R, Baurmeister U, Brunet P, Cohen G, Glorieux G, Jankowski J. A bench to bedside view of uremic toxins. J Am Soc Nephrol 2008;19:863-70.
14. Hutchison CA, Cockwell P, Reid S, etal. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol 2007;18:886-95.
15. Morgera S, Haase M, Kuss T, etal. Pilot study on the effects of high cutoff hemofiltration on the need for norepinephrine in septic patients with acute renal failure. Crit Care Med 2006;34:2099-104.
16. Morgera S, Rocktaschel J, Haase M, etal. Intermittent high permeability hemofiltration in septic patients with acute renal failure. Intensive Care Med 2003;29:1989-95.
17. Haase M, Bellomo R, Baldwin I, etal. Hemodialysis membrane with a high-molecular-weight cutoff and cytokine levels in sepsis complicated by acute renal failure: a phase 1 randomized trial. Am J Kidney Dis 2007;50:296-304.
18. Daugirdas JT. Simplified equations for monitoring Kt/V, PCRn, eKt/V, and ePCRn. Adv Ren Replace Ther 1995;2:295-304.
19. Ritz E. Atherosclerosis in dialyzed patients. Blood Purif 2004;22:28-37.
20. Hutchison CA, Bradwell AR, Cook M, etal. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol 2009;4:745-54.
21. Dinesh K, Kunaparaju S, Cape K, Flythe JE, Feldman HI, Brunelli SM. A model of systolic blood pressure during the course of dialysis and clinical factors associated with various blood pressure behaviors. Am J Kidney Dis 2011;58:794-803.
22. Uchino S, Bellomo R, Morimatsu H, etal. Cytokine dialysis: an ex vivo study. ASAIO J 2002;48:650-3.
23. Hutchison CA, Harding S, Mead G, etal. Serum free-light chain removal by high cutoff hemodialysis: optimizing removal and supportive care. Artif Organs 2008;32:910-7.
24. Morgera S, Slowinski T, Melzer C, etal. Renal replacement therapy with high-cutoff hemofilters: impact of convection and diffusion on cytokine clearances and protein status. Am J Kidney Dis 2004;43:444-53.
25. Perl J, Huckvale K, Chellar M, John B, Davies SJ. Peritoneal protein clearance and not peritoneal membrane transport status predicts survival in a contemporary cohort of peritoneal dialysis patients. Clin J Am Soc Nephrol 2009;4:1201-6.
26. Balafa O, Halbesma N, Struijk DG, Dekker FW, Krediet RT. Peritoneal albumin and protein losses do not predict outcome in peritoneal dialysis patients. Clin J Am Soc Nephrol 2011;6:561-6.
27. Girndt M, Kaul H, Sester U, etal. Anti-inflammatory interleukin-10 genotype protects dialysis patients from cardiovascular events. Kidney Int 2002;62:949-55.
28. Greenberg JD, Kremer JM, Curtis JR, etal. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:576-82.
29. Ulrich C, Heine GH, Garcia P, etal. Increased expression of monocytic angiotensin converting enzyme in dialysis patients with cardiovascular disease. Nephrol Dial Transplant 2006;21:1596-602.